Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution

Condition:   Allergic Conjunctivitis Interventions:   Drug: rimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo);   Drug: Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution Sponsor:   Bausch & Lomb Incorporated Not yet recruiting

Source: ClinicalTrials.gov - April 17, 2023 Category: Research Source Type: clinical trials